Automation Partnership and Loughborough University in five-year
collaboration to develop regenerative medicine
5 February 2010
The Automation Partnership (TAP), a world leader in the design
and development of innovative automation systems for life science
applications, and the EPSRC Centre for Innovative Manufacturing in
Regenerative Medicine at Loughborough University are continuing their
collaboration into a second five-year phase.
This follows the recent announcement by UK Prime Minister, Gordon Brown
and Lord Mandelson, UK Secretary of State, Department for Business,
Innovation and Skills of a £5.33 million grant to the Centre.
TAP’s new five-year partnership with EPSRC Centre for Innovative
Manufacturing in Regenerative Medicine will mean the further development
and testing of its CompacT CellBase system for culturing clinically
applicable stem cells in a Good Manufacturing Practice (GMP)
environment. Additionally, the funding will allow TAP to begin new
research with the centre to develop ambr, TAP’s advanced microscale
bioreactor that mimics the characteristics of classical bioreactors.
This project will enable the centre to explore the use of alternative
technology platforms to ensure high quality stem cell therapies are
manufactured both rapidly and cost-effectively.
This new collaboration is a continuation of the work TAP began as
part of the remedi (regenerative medicine — a new industry) EPSRC Grand
Challenge consortium in 2005 and has contributed to remedi achieving
three world firsts in automated cell culture, including production in a
CompacT CellBase of a clinical grade neuronal stem cell line.
David Newble, TAP’s CEO stated: "We are delighted our collaboration
with the EPSRC Centre for Innovative Manufacturing in Regenerative
Medicine will continue to be funded and is a great endorsement of the
success we have all achieved with the remedi consortium. Utilising and
developing TAP’s innovative technology is firmly at the heart of this
partnership and sends a clear signal that TAP is leading the way in
regenerative medicine and playing a vital role in making affordable new
stem cell therapies a reality.”